Loading
Life sciences · Journal article
European Thyroid Journal · September 28, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Background Poorly differentiated (PDTC) and anaplastic thyroid carcinoma (ATC) are rare, aggressive malignancies with limited treatment options. Although targeted therapies for tumours harbouring BRAF V600E mutations or fusions involving NTRK1, NTRK2, NTRK3, or RET have expanded treatment options, most patients lack such actionable alterations and urgently require alternative therapeutic strategies. Immune checkpoint blockade (ICB) has emerged as a promising approach, but its real-world application is limited by restricted trial access, reimbursement challenges, and the aggressive course of these diseases. Methods We retrospectively analysed the Essen ATC/PDTC cohort (June 2018 - February 2024) to evaluate the real-world efficacy of lenvatinib plus pembrolizumab (LEN-PEM) in heavily pretreated patients, including PDTC cases progressing after ≥2 prior tyrosine kinase inhibitors and ATC cases treated with upfront (radio-)chemotherapy. Results Among the five patients with PDTC, four achieved a partial response, and one achieved durable stable disease (>50 months), corresponding to an objective response rate (ORR) of 4/5 and a clinical benefit rate (CBR) of 5/5. Median progression-free survival (PFS) and overall survival (OS) from LEN-PEM initiation were 29.1 and 34.9 months, respectively; median OS from diagnosis was not reached. Among the ten patients with ATC, four achieved a partial response, and three achieved stable disease, corresponding to an ORR of 4/10 and a CBR of 7/10. Median PFS and OS from LEN-PEM initiation were 7.6 and 9.9 months, respectively, and median OS from diagnosis was 24.3 months. Conclusion LEN-PEM demonstrates meaningful clinical activity in pretreated PDTC and ATC patients, supporting its use as a later-line therapeutic option.